For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback